Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*
暂无分享,去创建一个
B. Fries | S. Nachman | E. Bennett-Guerrero | J. Hearing | J. Romeiser | Lillian R. Talbot | H. Salman | Laura M. Generale | T. Ahmed | M. Cosgrove | L. Mamone | Sunitha M. Singh | Dishaw D Holiprosad | Alex T. Freedenberg | J. Carter | Nicholas J Browne | Margaret Shevik | Margaret A Andrew
[1] E. Bennett-Guerrero,et al. Impact of serological and PCR testing requirements on the selection of COVID‐19 convalescent plasma donors , 2021, Transfusion.
[2] Ga-Ram Hwang,et al. Neutralizing activity to SARS‐CoV‐2 of convalescent and control plasma used in a randomized controlled trial , 2021, Transfusion.
[3] F. Polack,et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.
[4] D. Follmann,et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.
[5] T. Bhatnagar,et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.
[6] Nicole M. Bouvier,et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study , 2020, Nature Medicine.
[7] J. Bailey,et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study , 2020, medRxiv.
[8] A. Casadevall,et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience , 2020, medRxiv.
[9] R. Olsen,et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality , 2020, The American Journal of Pathology.
[10] Patrick W. Johnson,et al. Safety Update , 2020, Mayo Clinic Proceedings.
[11] Patrick W. Johnson,et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. , 2020, The Journal of clinical investigation.
[12] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[13] S. W. Long,et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma , 2020, The American Journal of Pathology.
[14] S. W. Long,et al. Treatment of COVID-19 Patients with Convalescent Plasma , 2020, The American Journal of Pathology.
[15] Qi Zhang,et al. Treatment of 6 COVID-19 Patients with Convalescent Plasma , 2020, medRxiv.
[16] T. Lv,et al. Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China , 2020, Journal of medical virology.
[17] T. Jodlowski,et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[18] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[19] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[20] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[21] M. Hughes,et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Respiratory medicine.
[22] G. Marano,et al. Convalescent plasma: new evidence for an old therapeutic tool? , 2016, Blood transfusion = Trasfusione del sangue.
[23] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[24] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.